Aquestive Therapeutics (AQST) Interest Expenses (2017 - 2026)

Aquestive Therapeutics' Interest Expenses history runs 10 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 4.35% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $11.2 million (up 1.09% YoY), while the FY2025 annual figure was $11.1 million, changed 0.02% from the prior year.
• Interest Expenses was $2.9 million for Q1 2026 at Aquestive Therapeutics, up from $2.8 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $2.9 million in Q1 2026 to a low of $1.3 million in Q3 2023.
• Historically, Interest Expenses has averaged $2.2 million across 5 years, with a median of $2.8 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Interest Expenses tumbled 41.4% in 2022, then jumped 121.34% in 2024.
• A 5-year view of Interest Expenses shows it stood at $1.6 million in 2022, then jumped by 37.76% to $2.3 million in 2023, then gained by 22.26% to $2.8 million in 2024, then fell by 0.04% to $2.8 million in 2025, then rose by 4.5% to $2.9 million in 2026.
• The last three Interest Expenses figures came in at $2.9 million (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.